Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
BTC Health Limited operates as a Pooled Development Fund, overseen by LHC Capital Partners Pty Ltd. The fund strategically deploys capital across various corporate development stages, from initial seed and startup funding to early, mid, and late-stage venture growth, and into emerging and established growth companies. Its investment focus lies primarily within the healthcare and biotechnology industries, with a specific emphasis on groundbreaking areas such as post-genomics, which encompasses functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. It also targets stem cell biology, particularly stem cell therapies. Other key areas of interest include convergent technologies, like biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics; silicon biology, involving structure-based drug design, virtual screening, computational library design, and in silico ADME/tox; and nanomedicine. The fund exclusively supports businesses located in Australia, investing in both publicly traded and privately held enterprises.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI